4.3 Article

Experiences of an outpatient infusion center with intravenous magnesium therapy for status migrainosus

期刊

CLINICAL NEUROLOGY AND NEUROSURGERY
卷 178, 期 -, 页码 31-35

出版社

ELSEVIER
DOI: 10.1016/j.clineuro.2019.01.007

关键词

Magnesium; Migraine; Headache; Pain; PGIC; Observational; Retrospective

向作者/读者索取更多资源

Objectives: Exploratory study to investigate the effectiveness of intravenous magnesium as an abortive for status migrainosus in an outpatient infusion center, and characterize the patients who benefit from the therapy. Patients & methods: Retrospective analysis of 234 migraine patients who received IV magnesium as a headache abortive, at the headache clinic of University of Southern California. Additional intramuscular (IM) injections for nausea (prochlorperazine, odansetron, metoclopramide) or for refractory pain (ketorolac, dexamethasone, sumatriptan, dihydroergotamine), were administered as necessary. Immediately before and after treatment, self-reported pain levels were recorded using an 11-point numeric pain rating scale (0-10). Results: Our patient sample has a mean age of 44 years and was predominantly female (79%). 36 (19%) had migraine with aura. Overall, pain score decreased from 5.46 +/- 2.39 to 3.56 +/- 2.75 (P < 0.001) after magnesium infusion. One hundred twenty-seven (54%) patients had clinically significant pain reduction, as defined by pain decrease >= 30%. One hundred and four patients (44%) received IV magnesium and did not require additional intramuscular (IM) medications for pain. In patients who did not receive additional IM medications for pain, pain score decreased from 4.76 +/- 2.41 to 2.95 +/- 2.70 (p < 0.001), and 61 out of 104 (59%) experienced >= 30% pain reduction. Patients with less severe pain tended to have a better response than patients with more severe pain, as patients with >= 30% pain reduction had a significantly lower pre-treatment pain score (p = 0.018). Conclusion: For a subset of patients with status migrainosus, IV magnesium therapy results in clinically significant pain relief without the need for intramuscular pain medications. Therefore, IV magnesium may be useful as a cost-effective first-line parental therapy for status migrainosus, especially for patients who initially present with lower pain intensity.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.3
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据